Advertisement

Prospective Clinical Correlation of the Histoculture Drug Response Assay for Ovarian Cancer

  • Robert M. Hoffman
  • Phill-Seung Jung
  • Moon-Bo Kim
  • Joo-Hyun Nam
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1760)

Abstract

The histoculture drug response assay (HDRA) has been correlated clinically to a number of cancer types (please see Chaps.  7 11 of the present volume). The present chapter reviews the clinical trials of the HDRA for ovarian cancer. A prospective clinical trial of the HDRA for advanced epithelial ovarian cancer (AEOC) was performed at Asan Medical Center, Seoul, Korea. The clinical trial compared the efficacy of first-line therapy paclitaxel and carboplatinum in the HDRA and the clinical response for the patients whose tumors were tested in the HDRA. A series of patients (104) were treated with adjuvant combination chemotherapy of paclitaxel and carboplatinum after primary cytoreductive surgery. Tumor fragments were cultured on Gelfoam® and tested with paclitaxel and carboplatinum and evaluated with the MTT endpoint. Patients were categorized into two groups as either sensitive to both drugs (SS) or not sensitive to one or both drugs (R) based on HDRA results. The recurrence rate was much lower in the SS group compared to the R group, 29.2% vs. 69.8%, respectively. The SS group had a significantly longer progression-free survival compared to the R group, 34.0 months vs. 16.0 months, respectively. In another clinical trial, the HDRA was performed on 85 cases of ovarian cancer and 97% were evaluable. HDRA results were correlated to clinical response of 15 patients who received cisplatinum-based therapy that included doxorubicin and cyclophosphamide (CAP therapy). The true-positive rate was 88%, the true-negative rate was 86%, the sensitivity was 88%, the specificity was 86%, and the accurate prediction rate was 87% when HDRA results were compared to the response of the treated patients.

Key words

Gelfoam® histoculture HDRA Ovarian cancer Paclitaxel Carboplatinum Cisplatinum Recurrence Progression Survival Correlation Prospective Clinical trial 

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29CrossRefPubMedGoogle Scholar
  2. 2.
    Joo WD, Lee JY, Kim JH, Yoo HJ, Roh HJ, Park JY, Kim DY, Kim YM, Kim YT, Nam JH (2009) Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J Gynecol Oncol 20:96–100CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM (1987) In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A 84:5029–5033CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Leighton J (1951) A sponge matrix method for tissue culture; formation of organized aggregates of cells in vitro. J Natl Cancer Inst 12:545–561PubMedGoogle Scholar
  5. 5.
    Hoffman RM (1991) In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 5:133–143CrossRefPubMedGoogle Scholar
  6. 6.
    Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M et al (1992) High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51:489–498CrossRefPubMedGoogle Scholar
  7. 7.
    Furukawa T, Kubota T, Watanabe M, Kase S, Takahara T, Yamaguchi H, Takeuchi T, Teramoto T, Ishibiki K, Kitajima M et al (1992) Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and the MTT end-point. Anticancer Res 12:1377–1382PubMedGoogle Scholar
  8. 8.
    Hoffman RM (1993) To do tissue culture in two or three dimensions? That is the question. Stem Cells 11:105–111CrossRefPubMedGoogle Scholar
  9. 9.
    Hoffman RM (1993) In vitro assays for chemotherapy sensitivity. Crit Rev Oncol Hematol 15:99–111CrossRefPubMedGoogle Scholar
  10. 10.
    Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H et al (1995) Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537–1543PubMedGoogle Scholar
  11. 11.
    Furukawa T, Kubota T, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305–311PubMedGoogle Scholar
  12. 12.
    Hoffman RM (2010) Histocultures and their use. In: Encyclopedia of Life Sciences. John Wiley and Sons, Ltd, Chichester.  https://doi.org/10.1002/9780470015902.a0002573.pub2 Google Scholar
  13. 13.
    Nakamura J, Imai E, Yoshihama M, Sasano H, Kubota T (1998) Histoculture drug response assay, a possible examination system for predicting the antitumor effect of aromatase inhibitors in patients with breast cancer. Anticancer Res 18:125–128PubMedGoogle Scholar
  14. 14.
    Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS, Lee JS (2009) Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Color Dis 24:209–218CrossRefGoogle Scholar
  15. 15.
    Yoon YS, Kim CW, Roh SA, Cho DH, Kim GP, Hong YS, Kim TW, Kim MB, Kim JC (2012) Applicability of histoculture drug response assays in colorectal cancer chemotherapy. Anticancer Res 32:3581–3586PubMedGoogle Scholar
  16. 16.
    Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Hoffman RM, Shah J (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442CrossRefPubMedGoogle Scholar
  17. 17.
    Hoffman RM (1991) Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 3:86–92PubMedGoogle Scholar
  18. 18.
    Yoshimasu T, Oura S, Maebeya S, Tanino H, Bessho T, Arimoto J, Sakurai T, Matsuyama K, Naito Y, Furukawa T, Yano T, Suzuma T, Hirai I (2000) Histoculture drug response assay on non-small-cell lung cancer. Gan To Kagaku Ryoho 27:717–722PubMedGoogle Scholar
  19. 19.
    Tamaki T, Oura S, Yoshimasu T, Ota F, Nakamura R, Shimizu Y, Kiyoi M, Naito K, Hirai Y, Okamura Y (2008) Histoculture drug response assay guided concurrent chemoradiotherapy for non-small cell lung cancer. Kyobu Geka 61:31–35PubMedGoogle Scholar
  20. 20.
    Tanahashi M, Yamada T, Moriyama S, Suzuki E, Niwa H (2008) The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer. Kyobu Geka 61:26–30PubMedGoogle Scholar
  21. 21.
    Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR, Hoffman RM (2000) Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20:2049–2054PubMedGoogle Scholar
  22. 22.
    Jung PS, Kim DY, Kim MB, Lee SW, Kim JH, Kim YM, Kim YT, Hoffman RM, Nam JH (2013) Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res 33:1029–1034PubMedGoogle Scholar
  23. 23.
    Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, Susumu N, Udagawa Y, Nozawa S (2005) Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 15:445–452CrossRefPubMedGoogle Scholar
  24. 24.
    Tobias JS, Griffiths CT (1976) Management of ovarian carcinoma; current concepts and future prospects. N Engl J Med 294:818–822CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Robert M. Hoffman
    • 1
    • 2
  • Phill-Seung Jung
    • 3
  • Moon-Bo Kim
    • 4
  • Joo-Hyun Nam
    • 3
  1. 1.AntiCancer Inc.San DiegoUSA
  2. 2.Department of SurgeryUniversity of CaliforniaSan DiegoUSA
  3. 3.Department of Obstetrics and GynecologyUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulSouth Korea
  4. 4.MetaBio InstituteSeoulSouth Korea

Personalised recommendations